High-Intensity Statins in Acute Coronary Syndrome Part 1: A look at the pharmacological properties of Statins and clinical trials on Statins in ACS
Article Sidebar
Main Article Content
Abstract
Acute coronary syndrome (ACS) is a term that encompasses a range of conditions associated with sudden, reduced blood flow to the heart. These conditions can range from unstable angina to myocardial infarction. Over the years, various therapeutic agents have been utilized to manage ACS and improve clinical outcomes. One of the mainstays of therapy for ACS has been the class of medications known as statins. We discuss the role of statins in ACS, their mechanism of action, clinical evidence supporting their use, and the potential future directions in this area. This critical period post-ACS underscores the necessity for effective interventions to mitigate further risks. Among the therapeutic options available, statins play a pivotal role. These medications, when administered soon after an ACS event, offer significant benefits. Statins have the potential to stabilize atherosclerotic plaques, reduce the lipid component of these plaques, and decrease inflammation—all of which contribute to reducing the risk of subsequent cardiac events. Given the elevated risk immediately after an ACS event, initiating statin therapy as early as possible is imperative to ensure the maximum reduction in potential adverse outcomes. The timely introduction of statins can thus provide pronounced benefits during the period when the patient's risk is at its peak.
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
All open access articles published in the journal are distributed under the terms of the CC-BY-NC-SA 4.0 license (Creative Commons Attribution-Non-commercial-ShareAlike 4.0 International License) which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original work is properly cited and distributed under the same license (ShareAlike). Under Creative Commons, authors retain copyright in their articles.
References
ENDO A. A historical perspective on the discovery of statins. Proceedings of the Japan Academy, Series B. 2010;86(5):484–93.
Liao JK, Laufs U. PLEIOTROPIC EFFECTS OF STATINS. Annu Rev Pharmacol Toxicol. 2005 Sep 22;45(1):89–118.
Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 1999 Dec;10(6):543–60.
Sposito AC, Chapman MJ. Statin Therapy in Acute Coronary Syndromes. Arterioscler Thromb Vasc Biol. 2002 Oct;22(10):1524–34.
Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997. Am J Cardiol. 1998 Mar;81(5):582–7.
Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture. Circ Res. 1998 Sep 7;83(5):490–500.
Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, et al. Antiinflammatory and Antiarteriosclerotic Actions of HMG-CoA Reductase Inhibitors in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis. Circ Res. 2001 Aug 31;89(5):415–21.
Lesnik P, Rouis M, Skarlatos S, Kruth HS, Chapman MJ. Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proceedings of the National Academy of Sciences. 1992 Nov;89(21):10370–4.
Rosenson RS, Lowe GDO. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 1998 Oct;140(2):271–80.
Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation. Circulation. 2001 May 8;103(18):2248–53.
Epstein SE, Talbot TL. Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris. Am J Cardiol. 1981 Oct 1;48(4):797–803.
Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation. 1986 May;73(5):865–76.
Kaski JC, Tousoulis D, Gavrielides S, McFadden E, Galassi AR, Crea F, et al. Comparison of epicardial coronary artery tone and reactivity in Prinzmetal’s variant angina and chronic stable angina pectoris. J Am Coll Cardiol. 1991 Apr;17(5):1058–62.
Angeli F, Reboldi G, Mazzotta G, Garofoli M, Cerasa MF, Verdecchia P. Statins in acute coronary syndrome: very early initiation and benefits. Ther Adv Cardiovasc Dis. 2012 Aug 11;6(4):163–74.
Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study. PLoS One. 2014 May 9;9(5):e96808.
Schwartz GG. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE> JAMA. 2001 Apr 4;285(13):1711.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine. 2004 Apr 8;350(15):1495–504.
Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2005 Oct;46(8):1405–10.
Hulten E, Jackson JL, Douglas K, George S, Villines TC. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. Arch Intern Med. 2006 Sep 25;166(17):1814.
Yu S, Jin J, Chen Z, Luo X. High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis. 2020 Dec 23;19(1):194.
Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther. 2007 Mar 10;5(2):177–93.
Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme TM. Expert Opin Pharmacother. 2004 May 2;5(5):1187–200.
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. JAMA. 2006 Apr 5;295(13):1556.
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine. 2009 Apr 2;360(14):1395–407.
Lablanche JM, Danchin N, Farnier M, Tedgui A, Vicaut E, Alonso J, et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc Dis. 2008 Jun;101(6):399–406.
Lablanche JM, Leone A, Merkely B, Morais J, Alonso J, Santini M, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Arch Cardiovasc Dis. 2010 Mar;103(3):160–9.
Stalenhoef AFH, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study†. Eur Heart J. 2005 Dec 1;26(24):2664–72.
Rogers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, et al. Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. JACC Heart Fail. 2014 Jun;2(3):289–97.
Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, et al. Effect of Rosuvastatin on Coronary Atheroma in Stable Coronary Artery Disease Multicenter Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). Circulation Journal. 2009;73(11):2110–7.
Fonseca FAH, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin. 2005 Aug 19;21(8):1307–15.
Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, et al. Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia. Cardiology. 2008;111(4):219–28.
Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). Am J Cardiol. 2007 Mar;99(5):673–80.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet. 2009 Apr;373(9670):1175–82.
Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol. 2012 May;109(9):1239–46.
Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol. 2005 Apr;100(2):309–16.
Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J. 2004 Apr;147(4):705–12.
Ballantyne CM, Bertolami M, Garcia HRH, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May;151(5):975.e1-975.e9.
Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, et al. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. JAMA. 2007 Mar 28;297(12):1344.
Willich SN, Englert H, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K, et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. European Journal of Cardiovascular Prevention & Rehabilitation. 2009 Apr;16(2):180–7.
Clearfield MB, Amerena J, Bassand JP, García HRH, Miller SS, Sosef FF, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006 Dec 21;7(1):35.
Sardella G, Conti G, Donahue M, Mancone M, Canali E, De Carlo C, et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: The ROMA trial. Catheterization and Cardiovascular Interventions. 2013 Jan 8;81(1).
Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine. 2011 Dec;365(22):2078–87.
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial). Am J Cardiol. 2003 Jul;92(2):152–60.
Berne C, Siewert-Delle A. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005 Dec 3;4(1):7